Saatja: Virve-Hella Haavam </O=JM/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A1F6C7CB077E4FB0B23582BBA114A550-VIRVE-HELLA HAAVAM>
Saaja: Juta Maar, Ester Timmas, Ülle Näksi
Teema: Sildfin taotlus 9T90-STOP
Tere!
Edastan taotluse ja ühtlasi ka RM nõusoleku sildfinantseerimisvahendite eraldamiseks.
Tervitades
Virve-Hella Haavam / Riigieelarve osakond
Tel: 611 3031 /
[email protected] <mailto:
[email protected]>
Rahandusministeerium / Suur-Ameerika 1, 10122 Tallinn
www.rahandusministeerium.ee <http://www.rahandusministeerium.ee>
STOP Consortium Agreement, Final Version, 2018-04-04
STOP
Science and Technology in childhood Obesity
Policy
Grant Agreement number 774548
Consortium Agreement
Call: H2020-SFS-2016-2017
Topic: SFS-39-2017
Type of Action: Research Innovation Action
1 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Table of Contents
1. Section: Definitions.............................................................................................................. 5
2. Section: Purpose ................................................................................................................. 6
3. Section: Entry into force, duration and termination .............................................................. 6
4. Section: Responsibilities of Parties...................................................................................... 6
5. Section: Liability towards each other ................................................................................... 8
6. Section: Governance structure ............................................................................................ 8
7. Section: Financial provisions ............................................................................................. 14
8. Section: Results ................................................................................................................ 16
9. Section: Access Rights ...................................................................................................... 18
10. Section: Non-disclosure of information ............................................................................ 21
11. Section: Miscellaneous.................................................................................................... 22
12. Section Signatures .......................................................................................................... 24
Attachment 1: Background included ...................................................................................... 49
Attachment 2: Accession document ...................................................................................... 61
Attachment 3: List of Third Parties for simplified transfer according to Section 8.3.2............. 62
Attachment 4: Identified Affiliated Entities according to Section 9.5 ...................................... 63
Attachment 5: Scientific Advisory Committee Agreement according to Section 6.5.4.1……..64
Attachment 6: Special Clauses pertaining to the involvement of the WHO…………………...68
2 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
CONSORTIUM AGREEMENT
THIS CONSORTIUM AGREEMENT is based upon
REGULATION (EU) No 1290/2013 OF THE EUROPEAN PARLIAMENT AND OF THE
COUNCIL of 11 December 2013 laying down the rules for the participation and dissemination in
“Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020)”
(hereinafter referred to as “Rules for Participation”), and the European Commission Multi-
beneficiary General Model Grant Agreement and its Annexes, and is made on 1st June 2018,
hereinafter referred to as the Effective Date
BETWEEN:
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, established in Exhibition
Road, South Kensington Campus, London, SW7 2AZ, UK, the Coordinator
INSTITUTO SUPERIORE DI SANITA, established in Viale Regina Elena 299, Roma 00161, Italy
TERVISE ARENGU INSTITUUT, established in Hiiu 42, Tallinn 11619, Estonia
INSTITUTO DI STUDI PER L’INTEGRAZIONE DEI SISTEMI, established in Largo Dei Lombardi
4, Roma 00186, Italy
UNIVERSITATEA DE MEDICINA SI FARMACIE VICTOR BABES TIMISOARA, established in
Piata Eftimie Murgu 2A, Timisoara 300041, Romania
INSTITUTO DE SAUDE PUBLICA DA UNIVERSIDADE DO PORTO, established in Rua das
Taipas, Porto 4050 600, Portugal
NATIONAL INSTITUTE FOR AGRICULTURAL RESEARCH (hereinafter “INRA”), with its
headquarters in 147 rue de l’Université – 75338 Paris cedex 07, France, represented by Mr
Philippe Mauguin, President and acting as delegate by Mrs. Camille Michon, Presidente of the
Research Center of Ile-de-France Versailles-Grignon
UNIVERSITEIT HASSELT, established in Martelarenlaan 42, Hasselt 3500, Belgium
EUROPEAN PUBLIC HEALTH ALLIANCE, established in Rue De Treves 49-51, Bruxelles
1040, Belgium
WORLD OBESITY FEDERATION, established in Gray’s Inn Road 107 CDH 2, London, WC1X
8TZ, UK
UNIVERZA V LJUBLJANI, established in Kongresni Trg 12, Ljubljana 1000, Slovenia
KAROLINSKA INSTITUTET, established in Nobels Vag 5, Stockholm 17177, Sweden
NACIONALNI INSTITUT ZA JAVNO ZDRAVJE, established in Trubarjeva Cesta 2, Ljubljana
1000, Slovenia
SVEUČILIŠTE U ZAGREBU, KINEZIOLOŠKI FAKULTET, established in Horvacanski Zavoj 15,
Zagreb, Croatia
3 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
THE UNIVERSITY OF AUCKLAND, established in Princes Street 24, Auckland 1010, New
Zealand
BARCELONA INSTITUTE FOR GLOBAL HEALTH FOUNDATION (hereinafter “ISGlobal”),
with domicile in Barcelona, carrer del Rosselló, 132, 5-2, provided with VAT number G-65341695,
represented by Mr. Gonzalo Vicente Lacambra, with National ID Nº 25.445.668-D and
professional domicile in Barcelona 08036, carrer del Rosselló, 132 5º 2ª; in his capacity of General
Manager and pursuant to the public deed authorized by the Notary of Barcelona Mr. Tomás
Giménez Duart, on January 20th, 2015, under number 116 of his protocol
UNIVERSITA DEGLI STUDI DI TORINO, established in Via Guiseppe Verdi 8, Torino 10124,
Italy
TERVEYDEN JA HYVINVOINNIN LAITOS, established in Mannerheimintie 166, Helsinki 00271,
Finland
WORLD HEALTH ORGANIZATION (hereinafter “WHO”), with its headquarters in Avenue Appia
20, 1211 Geneve 27, Switzerland
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P., established in Calle
Monforte De Lemos 5, Madrid 28029, Spain
DIREÇÃO-GERAL DA SAÚDE, established in Alameda D. Afonso Henriques, 45, Lisbon 1049-
005, Portugal
UNIVERSITY OF SOUTHERN CALIFORNIA on behalf of its KECK SCHOOL OF MEDICINE of
USC, established in 2001 N. Soto Street, Los Angeles 90033, United States
ETABLISSEMENT D’ENSEIGNEMENT SUPERIEUR CONSULAIRE HAUTES ETUDES
COMMERCIALES DE PARIS, established in Avenue De La Porte Champeret 8, Paris 75017,
France with a share capital of EUR 60 451 500, registered at the Paris Register of Businesses
and Companies under number 817 759 186, represented by Peter TODD, Dean
INSTITUT DES SCIENCES ET INDUSTRIES DU VIVANT ET DE L’ENVIRONNEMENT,
established in 16 rue Claude Bernard, 75 231 Paris Cedex 05, France
hereinafter, jointly or individually, referred to as ”Parties” or ”Party”
relating to the Action entitled
Science and Technology in childhood Obesity Policy under Grant Agreement 774548
in short
STOP
hereinafter referred to as “Project”
WHEREAS:
4 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
The Parties, having considerable experience in the field concerned, have submitted a proposal
for the Project to the Funding Authority as part of the Horizon 2020 – the Framework Programme
for Research and Innovation (2014-2020)
The Parties wish to specify or supplement binding commitments among themselves in addition to
the provisions of the specific grant agreement to be signed by the Parties and the Funding
Authority (hereinafter “Grant Agreement”).
The Parties are aware that this Consortium Agreement is based upon the DESCA model
consortium agreement.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
1. Section: Definitions
1.1. Definitions
Words beginning with a capital letter shall have the meaning defined either herein or in the Rules
for Participation (Article 2) or in the Grant Agreement including its Annexes.
1.2. Additional Definitions
“Consortium Body“:
Consortium Body means any management body described in the Governance Structure section
of this Consortium Agreement.
“Consortium Plan”
Consortium Plan means the description of the action and the related agreed budget as first
defined in the Grant Agreement and which may be updated by the General Assembly.
"Funding Authority"
Funding Authority means the body awarding the grant for the Project and is the European Union
represented by the European Commission.
“Defaulting Party”
Defaulting Party means a Party which the General Assembly has identified to be in breach of this
Consortium Agreement and/or the Grant Agreement as specified in Section 4.2 of this Consortium
Agreement.
“Needed”
means:
For the implementation of the Project:
Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks
assigned to the recipient Party would be technically or legally impossible, significantly delayed
such that completion of associated tasks under the Consortium Plan would not be reasonably
possible within the anticipated duration of the Project, or require significant additional financial or
human resources not foreseen in the Consortium Plan.
For Exploitation of own Results:
Access Rights are Needed if, without the grant of such Access Rights, the Exploitation of own
Results would be technically or legally impossible.
“Software”
Software means sequences of instructions to carry out a process in, or convertible into, a form
executable by a computer and fixed in any tangible medium of expression.
5 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
2. Section: Purpose
The purpose of this Consortium Agreement is to specify with respect to the Project the relationship
among the Parties, in particular concerning the organisation of the work between the Parties, the
management of the Project and the rights and obligations of the Parties concerning inter alia
liability, Access Rights and dispute resolution.
3. Section: Entry into force, duration and termination
3.1. Entry into force
An entity becomes a Party to this Consortium Agreement upon signature of this Consortium
Agreement by a duly authorised representative.
This Consortium Agreement shall have effect from the Effective Date identified at the beginning
of this Consortium Agreement.
An entity may accede to this Consortium Agreement upon signature of this accession document
(Attachment 2) by the new Party and counter-signature by the Coordinator. Such accession shall
have effect from the date identified in the accession document. The new Party will also accede to
the Grant Agreement using the relevant Grant Agreement Accession Form.
3.2. Duration and termination
This Consortium Agreement shall continue in full force and effect until complete fulfilment of all
obligations undertaken by the Parties under the Grant Agreement and under this Consortium
Agreement.
However, this Consortium Agreement or the participation of one or more Parties to it may be
terminated earlier in accordance with the terms of this Consortium Agreement and the Grant
Agreement.
If the Grant Agreement
- is not signed by the Funding Authority or a Beneficiary, or
- is terminated, or
- a Beneficiary’s participation in the Grant Agreement is terminated,
this Consortium Agreement shall automatically terminate in respect of the affected Party/ies,
subject to the provisions surviving the expiration or termination under Section 3.3 of this
Consortium Agreement.
3.3. Survival of rights and obligations
The provisions relating to Access Rights and Confidentiality, for the time period mentioned
therein, as well as for Liability, Applicable Law, Settlement of Disputes and Attachment 6 shall
survive the expiration or termination of this Consortium Agreement.
Termination shall not affect any rights or obligations of a Party leaving the Consortium incurred
prior to the date of termination, unless otherwise agreed between the General Assembly and the
leaving Party. This includes the obligation to provide all input, deliverables and documents for the
period of the leaving Party’s participation in the Project.
4. Section: Responsibilities of Parties
6 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
4.1. General principles
Each Party undertakes to take part in the efficient implementation of the Project, and to cooperate,
perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement and this
Consortium Agreement as may be reasonably required from it and in a manner of good faith as
prescribed by Belgian law.
Each Party undertakes to notify promptly, in accordance with the governance structure of the
Project, any significant information, fact, problem or delay likely to affect the Project.
Each Party shall promptly provide all information reasonably required by a Consortium Body or
by the Coordinator to carry out its tasks.
Without constituting any kind of warranty, each Party shall take reasonable measures to ensure
the accuracy of any information or materials it supplies to the other Parties.
4.2. Breach
In the event that a responsible Consortium Body identifies a breach by a Party of its obligations
under this Consortium Agreement or the Grant Agreement (e.g. improper implementation of the
project), the Coordinator or, if the Coordinator is in breach of its obligations, the Party appointed
by the General Assembly, will give formal notice to such Party requiring that such breach will be
remedied within 30 calendar days from the date of receipt of the written notice by the Party.
If such breach is substantial and is not remedied within that period or is not capable of remedy,
the General Assembly may decide to declare the Party to be a Defaulting Party and to decide on
the consequences thereof which may include termination of its participation.
4.3. Involvement of third parties
A Party that enters into a subcontract or otherwise involves third parties (including but not limited
to Affiliated Entities) in the Project remains responsible for carrying out its relevant part of the
Project and for such third party’s compliance with the provisions of this Consortium Agreement
and of the Grant Agreement. It shall ensure that the involvement of third parties does not affect
the rights and obligations of the other Parties under this Consortium Agreement and the Grant
Agreement.
4.4. Ethical and Regulatory approvals
A Party, where applicable, shall be responsible for securing all necessary ethical and regulatory
approvals from the relevant committee(s) before undertaking any part of the Project requiring
such approval. In line with Article 34.2 if the Grant Agreement, that Party shall provide the
Coordinator with copies of relevant documentation indicating that such approval has been
obtained.
4.5. Internal Reporting
In addition to the reporting schedule outlined in Grant Agreement Article 20 and in order to enable
the Coordinator to fulfil the reporting deliverables outlined in Annex I, the following reports will be
submitted to the Coordinator.
- A financial report containing an estimate of costs to date is required once every 6
months
- A Work Package interim report covering technical aspects is required once every 6
months
7 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
For the avoidance of doubt, each Party will provide a financial report for their own costs. The Work
Package reports will be compiled by the Work Package Leader but all Parties have the
responsibility to contribute to these reports.
5. Section: Liability towards each other
5.1. No warranties
In respect of any information or materials (including Results and Background) supplied by one
Party to another under the Project, no warranty or representation of any kind is made, given or
implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement of
any proprietary rights of third parties.
Therefore,
- the recipient Party shall in all cases be entirely and solely liable for the use to which it puts such
information and materials, and
- no Party granting Access Rights shall be liable in case of infringement of proprietary rights of a
third party resulting from any other Party (or its Affiliated Entities) exercising its Access Rights.
5.2. Limitations of contractual liability
No Party shall be responsible to any other Party for any indirect or consequential loss or similar
damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts to the fullest
extent permitted under Belgian law.
A Party’s aggregate liability towards the other Parties collectively shall be limited to once the
Party’s share of the total costs of the Project as identified in Annex 2 of the Grant Agreement
provided such damage was not caused by a wilful act or gross negligence.
The terms of this Consortium Agreement shall not be construed to amend or limit any Party’s
statutory liability.
5.3. Damage caused to third parties
Each Party shall be solely liable for any loss, damage or injury to third parties resulting from the
performance of the said Party’s obligations by it or on its behalf under this Consortium Agreement
or from its use of Results or Background.
5.4. Force Majeure
No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from
fulfilling its obligations under the Consortium Agreement by Force Majeure.
Each Party will notify the competent Consortium Bodies of any Force Majeure without undue
delay. If the consequences of Force Majeure for the Project are not overcome within 6 weeks
after such notification, the transfer of tasks - if any - shall be decided by the competent Consortium
Bodies.
6. Section: Governance structure
6.1. General structure
The organisational structure of the Consortium shall comprise the following Consortium Bodies:
General Assembly as the ultimate decision-making body of the consortium.
8 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Project Steering Committee as the primary governing body for the operational management of
the Project which shall report to and be accountable to the General Assembly
The Coordinator is the legal entity acting as the intermediary between the Parties and the Funding
Authority. The Coordinator shall, in addition to its responsibilities as a Party, perform the tasks
assigned to it as described in the Grant Agreement and this Consortium Agreement.
The Project Manager assists the Project Steering Committee and the Coordinator.
6.2. General operational procedures for all Consortium Bodies
6.2.1. Representation in meetings
Any Party which is a member of a Consortium Body (hereinafter referred to as "Member"):
- should be present or represented at any meeting;
- may appoint a substitute or a proxy to attend and vote at any meeting;
and shall participate in a cooperative manner in the meetings.
6.2.2. Preparation and organisation of meetings
6.2.2.1. Convening meetings
The chairperson of a Consortium Body shall convene meetings of that Consortium Body.
Ordinary Extraordinary meeting
meeting
General At least once a At any time upon written request of the Project Coordinator,
Assembly year Project Steering Committee or 1/3 of the Members of the
General Assembly
Project At least twice At any time upon written request of the Project Coordinator or
Steering per year any Member of the Project Steering Committee
Committee
6.2.2.2. Notice of a meeting
The chairperson of a Consortium Body shall give notice in writing of a meeting to each Member
of that Consortium Body as soon as possible and no later than the minimum number of days
preceding the meeting as indicated below.
Ordinary meeting Extraordinary meeting
General Assembly 28 calendar days 15 calendar days
Project Steering 14 calendar days 7 calendar days
Committee
6.2.2.3. Sending the agenda
The chairperson of a Consortium Body shall prepare and send each Member of that Consortium
Body a written (original) agenda no later than the minimum number of days preceding the meeting
as indicated below.
General Assembly 21 calendar days, 10 calendar days for an extraordinary meeting
Project Steering 7 calendar days
Committee
9 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
6.2.2.4. Adding agenda items:
Any agenda item requiring a decision by the Members of a Consortium Body must be identified
as such on the agenda.
Any Member of a Consortium Body may add an item to the original agenda by written notification
to all of the other Members of that Consortium Body up to the minimum number of days preceding
the meeting as indicated below.
General Assembly 14 calendar days, 7 calendar days for an extraordinary meeting
Project Steering 2 calendar days
Committee
6.2.2.5. During a meeting the Members of a Consortium Body present or represented can
unanimously agree to add a new item to the original agenda. However no decision may be taken
on this item if not all Members are represented at the meeting.
6.2.2.6. Meetings of each Consortium Body may also be held by teleconference or other
telecommunication means.
6.2.2.7. Decisions will only be binding once the relevant part of the Minutes has been
accepted according to Section 6.2.5.
6.2.2.8 Any decision may also be taken without a meeting if the Coordinator circulates to
all Members of the Consortium Body a written document, which is then agreed by the defined
majority (see Section 6.2.3) of all Members of the Consortium Body. Such document shall include
the deadline for responses.
Decisions taken without a meeting shall be considered as accepted if, within the period set out in
article 6.2.4.4, no Member has sent an objection in writing to the chairperson. The decisions will
be binding after the chairperson sends to all Members of the Consortium Body and to the
Coordinator a written notification of this acceptance.
6.2.3. Voting rules and quorum
6.2.3.1. Each Consortium Body shall not deliberate and decide validly unless two-thirds
(2/3) of its Members are present or represented (quorum). If the quorum is not reached, the
chairperson of the Consortium Body shall convene another ordinary meeting within 15 calendar
days. If in this meeting the quorum is not reached once more, the chairperson shall convene an
extraordinary meeting which shall be entitled to decide even if less than the quorum of Members
are present or represented.
6.2.3.2. Each Member of a Consortium Body present or represented in the meeting shall
have one vote.
6.2.3.3. A Party which the General Assembly has declared pursuant to Section 4.2 to be a
Defaulting Party may not exercise any vote or participate in any further Consortium Body decision-
making following the declaration of default.
6.2.3.4. Except where otherwise shown in this Consortium Agreement, decisions shall be
taken by a simple majority of the votes cast. In case of a tied vote the Coordinator will have the
casting vote.
6.2.4. Veto rights
6.2.4.1. A Party which can show that its own work, time for performance, costs, liabilities,
intellectual property rights or other legitimate interests would be severely affected by a decision
10 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
of a Consortium Body may exercise a veto with respect to the corresponding decision or relevant
part of the decision.
6.2.4.2. When the decision is foreseen on the original agenda, a Member may veto such
a decision during the meeting only.
6.2.4.3. When a decision has been taken on a new item added to the agenda before or
during the meeting, a Party may veto such decision during the meeting and/or within 15 calendar
days after the draft minutes of the meeting are sent. A Party that is not a Member of a particular
Consortium Body may veto a decision within the same number of calendar days after the draft
minutes of the meeting are sent.
6.2.4.4. When a decision has been taken without a meeting a Member may veto such
decision within 15 calendar days after written notification by the chairperson of the outcome of the
vote.
6.2.4.5. In case of exercise of veto, the Members of the related Consortium Body shall
make every effort to resolve the matter which occasioned the veto to the general satisfaction of
all Parties.
6.2.4.6. A Party may neither veto decisions relating to its identification to be in breach of
its obligations nor to its identification as a Defaulting Party. The Defaulting Party may not veto
decisions relating to its participation and termination in the consortium or the consequences of
them.
6.2.4.7. A Party requesting to leave the consortium may not veto decisions relating thereto.
6.2.5. Minutes of meetings
6.2.5.1. The chairperson of a Consortium Body shall produce written minutes of each
meeting which shall be the formal record of all decisions taken. He/she shall send the draft
minutes to all Members within 10 calendar days of the meeting.
6.2.5.2. The minutes shall be considered as accepted if, within 21 calendar days from
sending, no Member has sent an objection in writing to the chairperson with respect to the
accuracy of the draft of the minutes.
6.2.5.3. The chairperson shall send the accepted minutes to all the Members of the
Consortium Body and to the Coordinator, who shall safeguard them. If requested the Coordinator
shall provide authenticated duplicates to Parties.
6.3. Specific operational procedures for the Consortium Bodies
6.3.1. General Assembly
In addition to the rules described in Section 6.2, the following rules apply:
6.3.1.1. Members
6.3.1.1.1. The General Assembly shall consist of one representative of each Party
(hereinafter General Assembly Member).
6.3.1.1.2. Each General Assembly Member shall be deemed to be duly authorised to
deliberate, negotiate and decide on all matters listed in Section 6.3.1.2. of this Consortium
Agreement. However if the Member who attends the meeting is not authorised by his/her
institution to make a proposed decision on behalf of that institution, the Member will ensure that
he or she refers such decision to the authorised representative for his or her institution at the
earliest time possible and will inform the Coordinator of such referral. Notwithstanding this referral
the timescales described in Section 6 will be adhered to.
11 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
6.3.1.1.3. The Coordinator shall chair all meetings of the General Assembly, unless decided
otherwise in a meeting of the General Assembly.
6.3.1.1.4. The Parties agree to abide by all decisions of the General Assembly. This does
not prevent the Parties to submit a dispute to resolution in accordance with the provisions of
Settlement of disputes in Section 11.8.
6.3.1.2. Decisions
The General Assembly shall be free to act on its own initiative to formulate proposals and take
decisions in accordance with the procedures set out herein. In addition, all proposals made by
the Project Steering Committee shall also be considered and decided upon by the General
Assembly.
The following decisions shall be taken by the General Assembly:
Content, finances and intellectual property rights
- Proposals for changes to Annexes 1 and 2 of the Grant Agreement to be agreed by the
Funding Authority
- Changes to the Consortium Plan
- Modifications to Attachment 1 (Background Included)
- Additions to Attachment 3 (List of Third Parties for simplified transfer according to
Section 8.2.2)
- Additions to Attachment 4 (Identified Affiliated Entities)
Evolution of the consortium
- Entry of a new Party to the consortium and approval of the settlement on the conditions of the
accession of such a new Party
- Withdrawal of a Party from the consortium and the approval of the settlement on the conditions
of the withdrawal
- Identification of a breach by a Party of its obligations under this Consortium Agreement or the
Grant Agreement
- Declaration of a Party to be a Defaulting Party
- Remedies to be performed by a Defaulting Party
- Termination of a Defaulting Party’s participation in the consortium and measures relating
thereto
- Proposal to the Funding Authority for a change of the Coordinator
- Proposal to the Funding Authority for suspension of all or part of the Project
- Proposal to the Funding Authority for termination of the Project and the Consortium
Agreement
Appointments
On the basis of the Grant Agreement, the appointment if necessary of:
- Project Steering Committee Members
6.3.1.3 The voting requirements shown in Section 6.2.3.4 shall not apply to the following decisions
which shall instead require the unanimous vote of the General Assembly, with the exception that
the vote of a Party which is proposed to be declared in default shall not be considered on such
vote:
12 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
- Entry of a new entity to the Project and approval of the settlement of conditions of the accession
to the Project, including the Grant Agreement and Consortium Agreement, of such new entity
- Declaration of a Party to be a Defaulting Party
6.3.2. Project Steering Committee
6.4. In addition to the rules in Section 6.2, the following rules shall apply:
6.4.1.1. Members
The Project Steering Committee shall consist of the Coordinator, the Work Package Leaders and
the Project Manager.
The Coordinator shall chair all meetings of the Project Steering Committee, unless decided
otherwise by a majority of two-thirds.
6.4.1.2. Minutes of meetings
Minutes of Project Steering Committee meetings, once accepted, shall be sent by the Coordinator
to the General Assembly Members for information.
6.4.1.3. Tasks
6.4.1.3.1. The Project Steering Committee shall prepare the meetings, propose decisions
and prepare the agenda of the General Assembly according to Section 6.3.1.2.
6.4.1.3.2. The Project Steering Committee shall seek a consensus among the Parties.
6.4.1.3.3. The Project Steering Committee shall be responsible for the proper execution and
implementation of the decisions of the General Assembly.
6.4.1.3.4. The Project Steering Committee shall monitor the effective and efficient
implementation of the Project.
6.4.1.3.5. In addition, the Project Steering Committee shall collect information at least every
6 months on the progress of the Project, examine that information to assess the compliance of
the Project with the Consortium Plan and, if necessary, propose modifications of the Consortium
Plan to the General Assembly.
6.4.1.3.6. The Project Steering Committee shall:
- support the Coordinator in preparing meetings with the Funding Authority and in preparing
related data and deliverables
- prepare the content and timing of press releases and joint publications by the consortium or
proposed by the Funding Authority in respect of the procedures of the Grant Agreement Article
29.
6.4.1.3.7. In the case of abolished tasks as a result of a decision of the General Assembly,
the Project Steering Committee shall advise the General Assembly on ways to rearrange tasks
and budgets of the Parties concerned. Such rearrangement shall take into consideration the
legitimate commitments taken prior to the decisions, which cannot be cancelled.
6.5. Coordinator
6.5.1. The Coordinator shall be the intermediary between the Parties and the Funding Authority
and shall perform all tasks assigned to it as described in the Grant Agreement and in this
Consortium Agreement.
6.5.2. In particular, the Coordinator shall be responsible for:
− monitoring compliance by the Parties with their obligations
− keeping the address list of Members and other contact persons updated and available
13 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
− collecting, reviewing to verify consistency and submitting reports, other deliverables (including
financial statements and related certifications) and specific requested documents to the
Funding Authority
− transmitting documents and information connected with the Project to any other Parties
concerned
− administering the financial contribution of the Funding Authority and fulfilling the financial tasks
described in Section 7.3
− providing, upon request, the Parties with official copies or originals of documents that are in
the sole possession of the Coordinator when such copies or originals are necessary for the
Parties to present claims.
− executing on behalf of the Parties the Scientific Advisory Committee Paricipation and
Confidentiality Agreement in Attachment 5 with a Scientific Advisory Committee Advisor as
detailed in 6.5.4.1
If one or more of the Parties is late in submission of any project deliverable, the Coordinator may
nevertheless submit the other ’Parties’ project deliverables and all other documents required by
the Grant Agreement to the Funding Authority in time.
6.5.3. If the Coordinator fails in its coordination tasks, the General Assembly may propose to the
Funding Authority to change the Coordinator.
6.5.4. The Coordinator shall not be entitled to act or to make legally binding declarations on
behalf of any other Party or of the consortium, unless explicitly stated otherwise in the Grant
Agreement or this Consortium Agreement.
6.5.4.1. The Coordinator is authorised on behalf of the Parties to enter into a Scientific Advisory
Committee Paricipation and Confidentiality agreement with Scientific Advisory Committee
Advisor, to cover such Advisor’s obligations of confidentiality and/or performance in the
Advisor’s interaction with the Parties to this Consortium Agreement, the template for such
agreement attached at Attachment 5 to this Consortium Agreement. Amendments and
modifications to the template in Attachment 5 require the prior written agreement of the Parties.
6.5.5. The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium
Agreement and in the Grant Agreement.
6.6. Project Manager
The Project Manager shall assist and facilitate the work of the Project Steering Committee and
the Coordinator for executing the decisions of the General Assembly as well as the day-to-day
management of the Project.
6.7. Scientific Advisory Committee (SAC)
A Scientific Advisory Committee (SAC) will be appointed and steered by the General Assembly.
The SAC shall assist and facilitate the decisions made by the General Assembly. The Coordinator
will ensure that a non-disclosure agreement is executed between all Parties and each SAC
member. Its terms shall be not less stringent than those stipulated in this Consortium
Agreement,and it shall be concluded no later than 60 calendar days after their nomination or
before any confidential information will be exchanged, whichever date is earlier. The Coordinator
shall write the minutes of the SAC meetings and prepare the implementation of the SACs
suggestions.
7. Section: Financial provisions
7.1. General Principles
14 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
7.1.1. Distribution of Financial Contribution
The financial contribution of the Funding Authority to the Project shall be distributed by the
Coordinator according to:
- the Consortium Plan and in accordance with the Grant Agreement
- the approval of reports by the Funding Authority, and
- the provisions of payment in Section 7.3.
A Party shall be funded only for its tasks carried out in accordance with the Consortium Plan.
7.1.2. Justifying Costs
In accordance with its own usual accounting and management principles and practices, each
Party shall be solely responsible for justifying its costs with respect to the Project towards the
Funding Authority. Neither the Coordinator nor any of the other Parties shall be in any way liable
or responsible for such justification of costs towards the Funding Authority.
7.1.3. Funding Principles
A Party that spends less than its allocated share of the budget as set out in the Consortium Plan
or – in case of reimbursement via unit costs - implements less units than foreseen in the
Consortium Plan will be funded in accordance with its actual duly justified eligible costs only.
A Party that spends more than its allocated share of the budget as set out in the Consortium Plan
will be funded only in respect of duly justified eligible costs up to an amount not exceeding that
share.
7.1.4. Return of excess payments; receipts
7.1.4.1. In any case of a Party having received excess payments, the Party has to return
the relevant amount to the Coordinator without undue delay.
7.1.4.2. In case a Party earns any receipt that is deductible from the total funding as set
out in the Consortium Plan, the deduction is only directed toward the Party earning such income.
The other Parties’ financial share of the budget shall not be affected by one Party’s receipt. In
case the relevant receipt is more than the allocated share of the Party as set out in the Consortium
Plan, the Party shall reimburse the funding reduction suffered by other Parties.
7.1.5. Financial Consequences of the termination of the participation of a Party
A Party leaving the consortium shall refund any payments it has received in excess of the amount
of contribution accepted by the Funding Authority or another contributor. Furthermore a Defaulting
Party shall, within the limits specified in Section 5.2 of this Consortium Agreement, bear any
reasonable and justifiable additional costs occurring to the other Parties in order to perform its
and their tasks.
7.2. Budgeting
The budget set out in the Consortium Plan shall be valued in accordance with the usual
accounting and management principles and practices of the respective Parties.
7.3. Payments
7.3.1. Payments to Parties are the exclusive tasks of the Coordinator.
In particular, the Coordinator shall:
- notify the Party concerned promptly of the date and composition of the amount transferred to
its bank account, giving the relevant references
15 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
- perform diligently its tasks in the proper administration of any funds and in maintaining
financial accounts
- undertake to keep the Funding Authority’s financial contribution to the Project separated from
its normal business accounts, its own assets and property, except if the Coordinator is a Public
Body or is not entitled to do so due to statutory legislation.
With reference to Articles 21.2 and 21.3.2 of the Grant Agreement, no Party shall before the end
of the Project receive more than its allocated share of the maximum grant amount from which the
amounts retained by the Funding Authority for the Guarantee Fund and for the final payment have
been deducted.
7.3.2. The payment schedule, which contains the transfer of pre-financing and interim payments
to Parties, will be handled according to the following:
50% of funding of costs included in the Consortium Plan will be paid to Parties after receipt
from the Funding Authority of the pre-financing payment without undue delay and in conformity
with the provisions of the Grant Agreement. Each Party's share of the pre-financing payment
will be calculated in proportion to their share of the maximum grant amount.
The remaining 50% of each Party's share of the pre-financing payment will be distributed no later
than month 12 of the Project unless a Party is under-spending on its budget, in which case the
Project Steering Committee will decide. As outlined in Section 4 the Parties will provide financial
reports to the Coordinator every 6 months. If the first 6-monthly report shows that a Party has
spent all of its initial pre-financing payment on activities outlined in the Consortium Plan or expects
to do so in the next 6 months then the remaining 50% of that Party's share of the pre-financing
will be distributed immediately. The Project Steering Committee may also agree to advancement
of pre-financing to a Party (up to an amount not exceeding that Party's share of the pre-financing
payment) in duly justified circumstances where the afore-mentioned condition is not met.
The Coordinator is entitled to withhold any payments due to a Party identified by a responsible
Consortium Body to be in breach of its obligations under this Consortium Agreement or the Grant
Agreement or to a Beneficiary which has not yet signed this Consortium Agreement.
The Coordinator is entitled to recover any payments already paid to a Defaulting Party.
8. Section: Results
8.1. Ownership of Results
Results are owned by the Party that generates them.
If the researchers of a Party are entitled to claim rights to the Results pursuant to national laws,
the Party concerned must ensure that it complies with its obligations under the Grant Agreement
and this Consortium Agreement.
8.2. Joint ownership
In the case of jointly owned Results, unless otherwise agreed:
- each of the joint owners shall be entitled to use their jointly owned Results for non-commercial
research activities on a royalty-free basis, and without requiring the prior consent of the other joint
owner(s), and
- each of the joint owners shall be entitled to otherwise exploit the jointly owned Results and to
grant non-exclusive licenses to third parties (without any right to sub-license), if the other joint
owners are given:
(a) at least 45 calendar days advance notice; and
16 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
(b) compensation under Fair and Reasonable Conditions.
8.3. Transfer of Results
8.3.1. Each Party may transfer ownership of its own Results following the procedures of the
Grant Agreement Article 30.
8.3.2. Each Party may identify specific third parties it intends to transfer the ownership of its
Results to in Attachment (3) to this Consortium Agreement. The other Parties hereby waive their
right to prior notice and their right to object to a transfer to listed third parties according to the
Grant Agreement Article 30.1. Any addition to Attachment (3) after signature of this Agreement
requires a decision of the General Assembly.
8.3.2.1. An Affiliated Entity is a third party. Therefore, if a Party wishes to transfer its Results to its
Affiliated Entity using the waiver of right to prior notice procedure, such Affiliated Entity should be
identified in Attachment 3. Where a Party has not made an entry in Attachment 3, the notice and
objection procedures set out in the Grant Agreement Article 30 shall apply at the point of any
intended transfer.
8.3.3. The transferring Party shall at the time of the transfer, inform the other Parties of such
transfer and shall ensure that the rights of the other Parties will not be affected by such transfer.
8.3.4. The Parties recognize that in the framework of a merger or an acquisition of an important
part of its assets, it may be impossible under applicable EU and national laws on mergers and
acquisitions for a Party to give the full 45 calendar days prior notice for the transfer as foreseen
in the Grant Agreement.
8.3.5. The obligations above apply only for as long as other Parties still have - or still may
request - Access Rights to the Results.
8.4. Dissemination
8.4.1. For the Avoidance of doubt, nothing in Art. 8.4 has impact on the confidentiality obligations
set out in Section 10.
8.4.2. Dissemination of own Results
8.4.2.1. During the Project the dissemination of own Results by one or several Parties
including but not restricted to publications and presentations, shall be governed by the procedure
of Article 29.1 of the Grant Agreement subject to the following provisions.
Prior notice of any planned publication shall be given to the other Parties at least 45 calendar
days before the publication. Any objection to the planned publication shall be made in accordance
with the Grant Agreement in writing to the Coordinator and to the Party or Parties proposing the
dissemination within 30 calendar days after the notification is sent. If no objection is made within
the time limit stated above, the publication is permitted.
8.4.2.2. An objection is justified if
(a) the protection of the objecting Party's Results or Background would be adversely affected
(b) the objecting Party's legitimate academic or commercial interests in relation to the Results or
Background would be significantly harmed.
(c) the publication contains Confidential Information of the objecting Party.
The objection has to include a precise request for necessary modifications.
8.4.2.3. If an objection has been raised the involved Parties shall discuss how to overcome
the justified grounds for the objection on a timely basis (for example by amendment to the planned
17 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
publication and/or by protecting information before publication) and the objecting Party shall not
unreasonably continue the opposition if appropriate measures are taken following the discussion.
Authorship on publications will be based on academic standards and custom. In accordance with
normal academic pratice, all investigators and contrinutors to a publication will be acknowledged,
always in compliance with recognised standards concerning publication and authorship.
8.5. The objecting Party can request a publication delay of not more than 90 calendar days
from the time it raises such an objection. After 90 calendar days the publication is permitted.
8.5.1. Dissemination of another Party’s unpublished Results or Background
A Party shall not include in any dissemination activity another Party's Results or Background
without obtaining the owning Party's prior written approval, unless they are already published.
8.5.2. Cooperation obligations
The Parties undertake to cooperate to allow the timely submission, examination, publication and
defence of any dissertation or thesis for a degree that includes their Results or Background
subject to the confidentiality and publication provisions agreed in this Consortium Agreement.
8.5.3. Use of names, logos or trademarks
Other than for use on the Project website to be developed by the Coordinator, for internal project
meetings and for activities in which the Project Results are disseminated (subject to this Section
8.4) for which permission to use the names and logos of the Parties is hereby deemed given,
nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising,
publicity or otherwise the name of the Parties or any of their logos or trademarks without their
prior written approval. The permitted use above shall be in accordance with the Parties’ graphic
guidelines as provided by the Parties in advance.
Any Project publication and/or outcome arising from input from the WHO shall include a disclaimer
to the effect that the WHO does not endorse or promote any particular commercial entity, service
or product that may be involved in, or be a result of, the Project.
8.6. Exclusive licenses
Where a Party wishes to grant an exclusive licence to its Results and seeks the written waiver of
the other Parties pursuant to Grant Agreement Article 30.2, the other Parties shall respond to the
requesting Party within 45 calendar days of the request. Any Party’s failure to respond (whether
in the negative or the positive) to the request within 45 calendar days shall be deemed to
constitute written approval of the waiver by the non-requesting Party.
9. Section: Access Rights
9.1. Background included
9.1.1. In Attachment 1, the Parties have identified and agreed on the Background for the Project
and have also, where relevant, informed each other that Access to specific Background is subject
to legal restrictions or limits.
Anything not identified in Attachment 1 shall not be the object of Access Right obligations
regarding Background.
9.1.2. Any Party can propose to the General Assembly to modify its Background in Attachment
1. A Party can add its own Background to Attachment 1 by notification to the General Assembly
but requires General Assembly approval to remove or modify Background in Attachment 1.
9.2. General Principles
18 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
9.2.1. Each Party shall implement its tasks in accordance with the Consortium Plan and shall
bear sole responsibility for ensuring that its acts within the Project do not knowingly infringe third
party property rights.
9.2.2. Any Access Rights granted expressly exclude any rights to sublicense unless expressly
stated otherwise.
9.2.3. Access Rights shall be free of any administrative transfer costs.
9.2.4. Access Rights are granted on a non-exclusive basis.
9.2.5. Results and Background shall be used only for the purposes for which Access Rights to it
have been granted.
9.2.6. All requests for Access Rights shall be made in writing. The decision on whether Access
Rights will be granted shall not be unreasonably delayed.
9.3. The granting of Access Rights may be made conditional on the acceptance of specific
conditions aimed at ensuring that these rights will be used only for the intended purpose and that
appropriate confidentiality obligations are in place.
9.3.1. The requesting Party must show that the Access Rights are Needed.
9.4. Access Rights for implementation
Access Rights to Results and Background Needed for the performance of the own work of a Party
under the Project shall be granted on a royalty-free basis, unless otherwise agreed for
Background in Attachment 1.
9.5. Access Rights for Exploitation
9.5.1. Access Rights to Results
9.6. Access Rights to Results if Needed for Exploitation of a Party's own Results shall be
granted on Fair and Reasonable Conditions.
Access Rights to Results for internal research and academic teaching activities shall be granted
on a royalty-free basis provided that no Results shall be accessed by or transferred or licensed
to any third party without the owning Party’s consent.
9.6.1. Access Rights to Background if Needed for Exploitation of a Party’s own Results shall be
granted on Fair and Reasonable Conditions.
9.6.2. A request for Access Rights may be made up to twelve months after the end of the Project
or, in the case of Section 9.7.2.1.2, after the termination of the requesting Party’s participation in
the Project.
9.7. Access Rights for Affiliated Entities
Affiliated Entities have Access Rights under the conditions of the Grant Agreement Articles 25.4
and 31.4 if they are identified in Attachment 4 (Identified Affiliated Entities) to this Consortium
Agreement.
Such Access Rights must be requested by the Affiliated Entity from the Party that holds the
Background or Results. Alternatively, the Party granting the Access Rights may individually agree
with the Party requesting the Access Rights to have the Access Rights include the right to
sublicense to the latter's Affiliated Entities [listed in Attachment 4]. Access Rights to Affiliated
Entities shall be granted on Fair and Reasonable Conditions and upon written bilateral agreement.
19 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Affiliated Entities which obtain Access Rights in return fulfil all confidentiality and other obligations
accepted by the Parties under the Grant Agreement or this Consortium Agreement as if such
Affiliated Entities were Parties.
Access Rights may be refused to Affiliated Entities if such granting is contrary to the legitimate
interests of the Party which owns the Background or the Results.
Access Rights granted to any Affiliated Entity are subject to the continuation of the Access Rights
of the Party to which it is affiliated, and shall automatically terminate upon termination of the
Access Rights granted to such Party.
Upon cessation of the status as an Affiliated Entity, any Access Rights granted to such former
Affiliated Entity shall lapse.
Further arrangements with Affiliated Entities may be negotiated in separate agreements.
9.8. Additional Access Rights
For the avoidance of doubt any grant of Access Rights not covered by the Grant Agreement or
this Consortium Agreement shall be at the absolute discretion of the owning Party and subject to
such terms and conditions as may be agreed between the owning and receiving Parties.
9.9. Access Rights for Parties entering or leaving the consortium
9.9.1. New Parties entering the consortium
As regards Results developed before the accession of the new Party, the new Party will be
granted Access Rights on the conditions applying for Access Rights to Background.
9.9.2. Parties leaving the consortium
9.9.2.1. Access Rights granted to a leaving Party
9.9.2.1.1. Defaulting Party
Access Rights granted to a Defaulting Party and such Party's right to request Access Rights shall
cease immediately upon receipt by the Defaulting Party of the formal notice of the decision of the
General Assembly to terminate its participation in the consortium.
9.9.2.1.2. Non-defaulting Party
A non-defaulting Party leaving voluntarily and with the other Parties' consent shall have Access
Rights to the Results developed until the date of the termination of its participation.
It may request Access Rights within the period of time specified in Section 9.4.3.
9.9.2.2. Access Rights to be granted by any leaving Party
Any Party leaving the Project shall continue to grant Access Rights pursuant to the Grant
Agreement and this Consortium Agreement as if it had remained a Party for the whole duration
of the Project.
9.10. Specific Provisions for Access Rights to Software
For the avoidance of doubt, the general provisions for Access Rights provided for in this Section
9 are applicable also to Software.
Parties’ Access Rights to Software do not include any right to receive source code or object code
ported to a certain hardware platform or any right to receive respective Software documentation
in any particular form or detail, but only as available from the Party granting the Access Rights.
20 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
10. Section: Non-disclosure of information
10.1. All information in whatever form or mode of communication which is disclosed by a Party
(the “Disclosing Party”) to any other Party (the “Recipient”) in connection with the Project during
its implementation and which has been explicitly marked as “confidential” at the time of disclosure
or, when disclosed orally, has been identified as confidential at the time of disclosure and has
been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest
as confidential information by the Disclosing Party, is “Confidential Information”.
10.2. The Recipients hereby undertake in addition and without prejudice to any commitment on
non-disclosure under the Grand Agreement, for a period of 4 years after the end of the Project:
- Not to use Confidential Information otherwise than for the purpose for which it was disclosed;
- not to disclose Confidential Information without the prior written consent by the Disclosing
Party;
- to ensure that internal distribution of Confidential Information by a Recipient shall take place
on a strict need-to-know basis; and
- to return to the Disclosing Party, or destroy, on request all Confidential Information that has
been disclosed to the Recipients including all copies thereof and to delete all information
stored in a machine readable form To the extent practically possible. The Recipients may
keep a copy to the extent it is required to keep, archive or store such Confidential Information
because of compliance with applicable laws and regulations or for the proof of on-going
obligations provided that the Recipient comply with the confidentiality obligations herein
contained with repsect to such copy for as long as the copy is retained.
10.3. The recipients shall be responsible for the fulfilment of the above obligations on the part
of their employees or third parties involved in the Project and shall ensure that they remain so
obliged, as far as legally possible, during and after the end of the Project and/or after the
termination of the contractual relationship with the employee or third party.
10.4. The above shall not apply for disclosure or use of Confidential Information, if and in so far
as the Recipient can show that:
- the Confidential Information has become or becomes publicly available by means other than
a breach of the Recipient’s confidentiality obligations;
- the Disclosing Party subsequently informs the Recipient that the Confidential Information is
no longer confidential;
- the Confidential Information is communicated to the Recipient without any obligation of
confidentiality by a third party who is to the best knowledge of the Recipient in lawful
possession thereof and under no obligation of confidence to the Disclosing Party;
- the disclosure or communication of the Confidential Information is foreseen by provisions of
the Grant Agreement;
- the Confidential Information, at any time, was developed by the Recipient completely
independently of any such disclosure by the Disclosing Party;
- the Confidential Information was already known to the Recipient prior to disclosure; or
- the Recipient is required to disclose the Confidential Information in order to comply with
applicable laws or regulations or with a court or administrative order, subject to the provision
Section 10.7 hereunder.
-
10.5. The Recipient shall apply the same degree of care with regard to the Confidential
Information disclosed within the scope of the Project as with its own confidential and/or proprietary
information, but in no case less than reasonable care
21 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
10.6. Each Party shall promptly advise the other Party in writing of any unauthorised disclosure,
misappropriation or misuse of Confidential Information after it becomes aware of such
unauthorised disclosure, misappropriation or misuse.
10.7. If any Party becomes aware that it will be required, or is likely to be required, to disclose
Confidential Information in order to comply with applicable laws or regulations or with a court or
administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure
- notify the Disclosing Party, and
- comply with the Disclosing Party’s reasonable instructions to protect the confidentiality of the
information (provided always that nothing contained herein shall be construed as a waiver of the
privileges and immunities enjoyed by the WHO and/or to submit WHO to any national court
jurisdiction).
11. Section: Miscellaneous
11.1. Attachments, inconsistencies and severability
This Consortium Agreement consists of this core text and
Attachment 1 (Background included)
Attachment 2 (Accession document)
Attachment 3 (List of Third Parties for simplified transfer according to Section 8.3.2)
Attachment 4 (Identified Affiliated Entities)
Attachment 5 (Scientific Advisory Committee Agreement according to Section 6.5.4.1)
Attachment 6 (Special Clauses pertaining to the involvement of the WHO)
In case the terms of this Consortium Agreement are in conflict with the terms of the Grant
Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments and
the core text of this Consortium Agreement, the latter shall prevail. The provisions in Attachment
6 prevail over any other provisions of this Consortium Agreement with regard to the WHO.
Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it
shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a
case, the Parties concerned shall be entitled to request that a valid and practicable provision be
negotiated that fulfils the purpose of the original provision.
11.2. No representation, partnership or agency
Except as otherwise provided in Section 6.5.4, no Party shall be entitled to act or to make legally
binding declarations on behalf of any other Party or of the consortium. Nothing in this Consortium
Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping
or any other kind of formal business grouping or entity between the Parties.
11.3. Notices and other communication
Any notice to be given under this Consortium Agreement shall be in writing to the addresses and
recipients as listed in the most current address list kept by the Coordinator.
Formal notices:
If it is required in this Consortium Agreement (Sections 4.2, 9.7.2.1.1, and 11.4) that a formal
notice, consent or approval shall be given, such notice shall be signed by an authorised
representative of a Party and shall either be served personally or sent by mail with recorded
delivery or telefax with receipt acknowledgement.
Other communication:
22 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Other communication between the Parties may also be effected by other means such as e-mail,
which fulfils the conditions of written form.
Any change of persons or contact details shall be notified promptly by the respective Party to the
Coordinator. The address list shall be accessible to all Parties.
11.4. Assignment and amendments
Except as set out in Section 8.3, no rights or obligations of the Parties arising from this Consortium
Agreement may be assigned or transferred, in whole or in part, to any third party without the other
Parties’ prior formal approval, such consent not to be unreasonably withheld, denied or delayed.
11.5. Amendments and modifications to the text of this Consortium Agreement not explicitly
listed in Section 6.3.1.2 require a separate written agreement to be signed between all Parties.
11.6. Mandatory national law
Nothing in this Consortium Agreement shall be deemed to require a Party to breach any
mandatory statutory law under which the Party is operating.
11.7. Language
This Consortium Agreement is drawn up in English, which language shall govern all documents,
notices, meetings, arbitral proceedings and processes relative thereto.
11.8. Applicable law
This Consortium Agreement shall be construed in accordance with and governed by the laws of
Belgium excluding its conflict of law provisions, except with regard to the WHO. Concerning WHO,
any matter relating to the interpretation or application of this Consortium Agreement not covered
by its terms shall be resolved by reference to the law of Belgium, supplemented, where
appropriate, by the general principles governing the law of international organisations and the
rules of general international law.
11.9. Settlement of disputes
The parties shall endeavour to settle their disputes amicably.
Any dispute, controversy or claim arising under, out of or relating to this contract and any
subsequent amendments of this contract, including, without limitation, its formation, validity,
binding effect, interpretation, performance, breach or termination shall be submitted to mediation
in accordance with the WIPO Mediation Rules. The place of mediation shall be Brussels unless
otherwise agreed upon. The language to be used in the mediation shall be English unless
otherwise agreed upon.
If, and to the extent that, any such dispute, controversy or claim has not been settled pursuant to
the mediation within 60 calendar days of the commencement of the mediation, it shall, upon the
filing of a Request for Arbitration by any Party, be referred to and finally determined by arbitration
in accordance with the WIPO Expedited Arbitration Rules. Alternatively, if, before the expiration
of the said period of 60 calendar days, any Party fails to participate or to continue to participate
in. the mediation, the dispute, controversy or claim shall, upon the filing of a Request for Arbitration
by another Party, be referred to and finally determined by arbitration in accordance with the WIPO
Expedited Arbitration Rules. The place of arbitration shall be Brussels unless otherwise agreed
upon. The language to be used in the arbitral proceedings shall be English unless otherwise
agreed upon.
23 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Nothing in this Consortium Agreement shall limit the Parties' right to seek injunctive relief in any
applicable competent court, except with regard to the WHO.
11.9 No one except a Party to this Agreement has any right to prevent the amendment of this
Agreement or its termination, and no one except a Party to this Agreement may enforce any
benefit conferred by this Agreement, unless Section 8.3 or Attachment 3 or any other provisions
of this Agreement expressly provide otherwise.
12. Section Signatures
AS WITNESS:
The Parties have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in as many separate signature pages per Party as there are Parties,
the day and year first above written.
24 / 68
STOP Consortium Agreement, Final Version, 201 8-04-04
UNIVERSITEIT HASSELT
\^ rbr"t
Signature(s)
Name(s) Luc de Schepper
Title(s) Rector Universiteit Hasselt
Date y'ltrLltpL{
32168
STOP Consortium Agreement, Final Version, 2018-04-04
UNIVERSITA DEGLI STUDI DI TORINO
Signature(s)
Name(s) Franco Veglio
Title(s) Professor, Head of Department
Date
41 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Attachment 1: Background included
According to the Grant Agreement (Article 24) Background is defined as “data, know-how or
information (…) that is needed to implement the action or exploit the results”. Because of this
need, Access Rights have to be granted in principle, but Parties must identify and agree amongst
them on the Background for the project. This is the purpose of this attachment.
PARTY 1
As to IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, it is agreed
between the Parties that, to the best of their knowledge (please choose),
No data, know-how or information of IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND
MEDICINE shall be Needed by another Party for implementation of the Project (Article 25.2 Grant
Agreement) or Exploitation of that other Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 2
As to INSTITUTO SUPERIORE DI SANITA, it is agreed between the Parties that, to the best of
their knowledge
No data, know-how or information of INSTITUTO SUPERIORE DI SANITA shall be Needed by
another Party for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of
that other Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 3
As to TERVISE ARENGU INSTITUUT, it is agreed between the Parties that, to the best of their
knowledge,
No data, know-how or information of TERVISE ARENGU INSTITUUT shall be Needed by another
Party for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other
Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 4
As to INSTITUTO DI STUDI PER L’INTEGRAZIONE DEI SISTEMI, it is agreed between the
Parties that, to the best of their knowledge,
No data, know-how or information of INSTITUTO DI STUDI PER L’INTEGRAZIONE DEI
SISTEMI shall be Needed by another Party for implementation of the Project (Article 25.2 Grant
Agreement) or Exploitation of that other Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
49 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
PARTY 5
As to UNIVERSITATEA DE MEDICINA SI FARMACIE VICTOR BABES TIMISOARA, it is
agreed between the Parties that, to the best of their knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Data on children’s height and Data will be retrieved from a Data can be used only for
weight in Romania health care register purposes and in format
administered by a company described in the data transfer
(Syonic) and appropriate agreement.
permissions and agreements
for data retrieval and transfer
are needed.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 6
As to INSTITUTO DE SAUDE PUBLICA DA UNIVERSIDADE DO PORTO, it is agreed between
the Parties that, to the best of their knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Cohort G21 Access to data will be granted
as far as ISPUP is legally
entitled to do so. Any data or
sample originated from the
G21 cohort is subjected to the
decision and agreement of
relevant scientific committee
and cohort coordination.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 7
As to NATIONAL INSTITUTE FOR AGRICULTURAL RESEARCH, it is agreed between the
Parties that, to the best of their knowledge,
50 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
KANTAR Worldpanel The access to the data is
Homescan data stricly rectricted to INRA
researchers.
Oqali Data Oqali data acess is subjected
to the decision and
agreement of relevant
scientific committee.
GNPD data The access to the data is
stricly rectricted to INRA
researchers who subscribe a
GNPD license.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 8
As to UNIVERSITEIT HASSELT, it is agreed between the Parties that, to the best of their
knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
ENVIRONAGE-cohort Data and samples from the
ENVIRONAGE cohort is
subjected to the cohort
Steering Committee. Before
data or samples transfer a
Data Transfer Agreement
(DTA) or Material Transfer
Agreement (MTA) should be
signed between
Institutions. The data will
exclude any
personal identification data.
Microcirculation The sampling protocol and
protocol to
analyse results can only be
used only for purposes within
the project
51 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
This represents the status at the time of signature of this Consortium Agreement.
PARTY 9
As to EUROPEAN PUBLIC HEALTH ALLIANCE, it is agreed between the Parties that, to the
best of their knowledge,
No data, know-how or information of EUROPEAN PUBLIC HEALTH ALLIANCE shall be Needed
by another Party for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation
of that other Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 10
As to WORLD OBESITY FEDERATION, it is agreed between the Parties that, to the best of their
knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
An interactive youth-focused The site will include material The site will include material
website created by the World generated from the project, generated from the project,
Obesity Federation shall be subject to the terms of this subject to the terms of this
owned by the World Obesity Consortium Agreement. Consortium Agreement.
Federation.
World Obesity Federation Dissemination subject to data Exploitation subject to data
organisational and individual protection regulations. Only protection regulations. Only
members’ contact details, and for use by the World Obesity for use by the World Obesity
the details of subscribers and Federation. Federation.
site visitors.
Aquired and generated press Only for use by the World Only for use by the World
and media contact lists, Obesity Federation. Obesity Federation.
incuding social media lists.
Data maps, graphics and Only for use by the World Only for use by the World
tables published on the World Obesity Federation unless Obesity Federation unless
Obesity Federation website, written consent is given. written consent is given.
along with their underlying
databases, surveys and
reports.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 11
As to UNIVERZA V LJUBLJANI, it is agreed between the Parties that, to the best of their
knowledge,
52 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Analysis of Healthy Lifestyle The data, available to Partners will be allowed to
project partners will exclude any use the data but any
personal identification data. publications, based on the
data, will have to be agreed
upon by the by the PI of the
University of Ljubljana. The PI
and the members of the
University of Ljubljana team
are going to be invited to
cooperate as authors of any
publications, but the actual
authorship will depend on the
actual input.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 12
As to KAROLINSKA INSTITUTET, it is agreed between the Parties that, to the best of their
knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
The MiniStopApp The App is owned by KI Subject to the rights of third
researcher Marie Löf and only parties (Marie Löf).
made available for academic No data, know-how or
research purposes and for information regarding the App
implementation of WP 8. will be needed by another
Party for exploitation of that
other Party’s Results.
The More and Less, a manual The ML is owned by KI Subject to the rights of third
and group parent program. researcher Paulina Nowicka party (Paulina Nowicka)
and only made available for No data, know-how or
academic research purposes information regarding the ML
and for implementation of WP Program will be needed by
8. another Party for exploitation
of that other Party’s Results.
53 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
This represents the status at the time of signature of this Consortium Agreement.
PARTY 13
As to NACIONALNI INSTITUT ZA JAVNO ZDRAVJE, it is agreed between the Parties that, to
the best of their knowledge,
No data, know-how or information of NACIONALNI INSTITUT ZA JAVNO ZDRAVJE shall be
Needed by another Party for implementation of the Project (Article 25.2 Grant Agreement) or
Exploitation of that other Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 14
As to SVEUČILIŠTE U ZAGREBU, KINEZIOLOŠKI FAKULTETT, it is agreed between the
Parties that, to the best of their knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Data collected within the
CRO-PALS study
This represents the status at the time of signature of this Consortium Agreement.
PARTY 15
As to THE UNIVERSITY OF AUCKLAND, it is agreed between the Parties that, to the best of
their knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
INFORMAS protocols, See See
databases, research materials http://www.informas.org/prot http://www.informas.org/prot
(evidence documents, good ocols/ for copyleft principles ocols/ for copyleft principles
practice examples, priority
setting systems, report
outputs) and training materials
This represents the status at the time of signature of this Consortium Agreement.
54 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
PARTY 16
As to BARCELONA INSTITUTE FOR GLOBAL HEALTH FOUNDATION, it is agreed between
the Parties that, to the best of their knowledge,
No data, know-how or information of BARCELONA INSTITUTE FOR GLOBAL HEALTH
FOUNDATION shall be Needed by another Party for implementation of the Project (Article 25.2
Grant Agreement) or Exploitation of that other Party’s Results (Article 25.3 Grant Agreement).
ISGlobal, hereby excludes from its obligation to grant Access Rights to Background all
Background generated by ISGlobal other than that generated by the scientists or research
group/s participating in the Consortium. Furthermore, any Background generated by the
participating scientists or research group/s which is not directly related to the present project is
excluded, as well as any Background derived from non EU-projects which ISGlobal, due to third
party rights, is not able to grant access rights to.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 17
As to UNIVERSITA DEGLI STUDI DI TORINO, it is agreed between the Parties that, to the best
of their knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Piccoli+ cohort Any data or sample originated
from the Piccolipiu cohort is
subjected to the decision and
agreement of cohort Steering
Committee. Data and Material
transfer is possible provided
that a Data Transfer
Agreement (DTA) or Material
Transfer Agreement (MTA)
about the transfer and use of
personal data or material is
signed between Institutions.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 18
As to TERVEYDEN JA HYVINVOINNIN LAITOS, it is agreed between the Parties that, to the
best of their knowledge,
55 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Data on children’s height and Data will be retrieved from the Data can be used only for
weight in Finland national health care register purposes and in format
administered by THL and described in the data transfer
appropriate permissions and agreement.
agreements for data retrieval
and transfer are needed.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 19
As to WORLD HEALTH ORGANIZATION, it is agreed between the Parties that, to the best of
their knowledge,
No data, know-how or information of WORLD HEALTH ORGANIZATION shall be Needed by
another Party for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of
that other Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 20
As to CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P., it is agreed
between the Parties that, to the best of their knowledge,
The following background is hereby identified and agreed upon for the Project. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Database of dietary intake, None envisaged None envisaged
lifestyle, physical activity,
biomarkers, and socio-
demographic determinants in
Spanish adolescents (11-17
years old) (Belongs to UIB)
Metabolomic analysis None envisaged None envisaged
(Belongs to UNAV)
Database corresponding to The database may be ceded Exploitation of the data and/or
the "Antropometría y partially or completely when results by parties other than
Nutrición Infantil de Valencia the CIBERESP Group 17 CIBERESP Group 17 lead by
principal investigator María principal investigator María
56 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
(ANIVA)” Project (Belongs to Morales Suárez-Varela Morales Suárez-Varela is
CIBERESP) deems it acceptable and may subject to: previous
be subject to conditions such authorization by said
as but not limited to: the CIBERESP Group 17
recuitment of personnel for principal investigator,
the CIBERESP Group 17 inclusion in any resulting
whose cost would be borne by publication of at least three
the party to whom the members of the project and
database is ceded. may be subject to other
conditions as considered by
the principal investigator on a
case by case basis.
Database corresponding to The database may be ceded Exploitation of the data and/or
the “Estudio sobre el estilo de partially or completely when results by parties other than
vida y la salud del recién the CIBERESP Group 17 CIBERESP Group 17 lead by
nacido” Project (Belongs to principal investigator María principal investigator María
CIBERESP) Morales Suárez-Varela Morales Suárez-Varela is
deems it acceptable and may subject to previous
be subject to conditions such authorization by said
as but not limited to: the CIBERESP Group 17
recuitment of personnel for principal investigator,
the CIBERESP Group 17 inclusion in any resulting
whose cost would be borne by publication of at least three
the party to whom the members of the project and
database is ceded. may be subject to other
conditions as considered by
the principal investigator on a
case by case basis.
Assessment of dietary intake, None envisaged None envisaged
lifestyle, physical activity and
fitness, obesity and co-
morbidities, clinical data, and
socio-demographic
determinants (multilevel
models) in all human
collectives. Oxidative and
antioxidant markers; nitrite &
nitrate measurements;
western-blot; RNA
expression; cometa-assay;
inflammatory biomarkers;
cytokines; lipid mediators (in
vivo, in vitro, and ex vivo).
Systematic reviews and
meta-analysis. Elaboration of
manuscripts and reports
Assessment of dietary intake, None envisaged None envisaged
lifestyle, physical activity and
fitness, obesity and co-
morbidities, clinical data, and
socio-demographic
57 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
determinants (multilevel
models) in all human
collectives. Metabolomic
analysis. Systematic reviews
and meta-analysis.
Elaboration of manuscripts
and reports
Analysis of human microbiota None envisaged None envisaged
under evolutionary and
biological systems’
perspective, applying
concepts from population
genetics and ecological
theory, by means of
computational tools
Spatial statistics. None envisaged None envisaged
Geographical Information
Systems. Hierarchical
models, multilevel models,
mixed models. Systematic
reviews, meta-analysis and
meta-regression. Non-
parametric methods.
Estimation of prevalence and
incidence from nonrandom
samples (two-part
econometric models).
Bayesian methods
Dietary assessment for None envisaged None envisaged
clinical and epidemiological
practice. Epidemiology of
obesity and type 2 diabetes,
prevention of childhood
obesity
Expertise in clinical care, None envisaged None envisaged
obesity management,
nutritional research
(phyisiological, cellular and
molecular), epidemiological
and clinical data statistical
analysis
This represents the status at the time of signature of this Consortium Agreement.
PARTY 21
As to DIREÇÃO-GERAL DA SAÚDE, it is agreed between the Parties that, to the best of their
knowledge,
58 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
No data, know-how or information of DIREÇÃO-GERAL DA SAÚDE shall be Needed by another
Party for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other
Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 22
As to UNIVERSITY OF SOUTHERN CALIFORNIA on behalf of its KECK SCHOOL OF
MEDICINE of USC, it is agreed between the Parties that, to the best of their knowledge,
No data, know-how or information of UNIVERSITY OF SOUTHERN CALIFORNIA on behalf of
its KECK SCHOOL OF MEDICINE of USC shall be Needed by another Party for implementation
of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Party’s Results (Article
25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 23
As to ETABLISSEMENT D’ENSEIGNEMENT SUPERIEUR CONSULAIRE HAUTES ETUDES
COMMERCIALES DE PARIS, it is agreed between the Parties that, to the best of their
knowledge,
No data, know-how or information of ETABLISSEMENT D’ENSEIGNEMENT SUPERIEUR
CONSULAIRE HAUTES ETUDES COMMERCIALES DE PARIS shall be Needed by another
Party for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other
Party’s Results (Article 25.3 Grant Agreement).
This represents the status at the time of signature of this Consortium Agreement.
PARTY 24
As to INSTITUT DES SCIENCES ET INDUSTRIES DU VIVANT ET DE L’ENVIRONNEMENT,
it is agreed between the Parties that, to the best of their knowledge,
The following background is hereby identified and agreed upon for the Project. Specific
limitations and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
(Article 25.2 Grant (Article 25.3 Grant
Agreement) Agreement)
Preference modelling
methods (including, external
preference mapping and
structural equation modelling)
that take into account
behavioral, and subjective
data.
59 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Collection and analysis of The data, available to
preference and behavioral partners will exclude any
data, in standardized and in personal identification data.
natural conditions
60 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Attachment 2: Accession document
ACCESSION
of a new Party to
[Acronym of the Project] Consortium Agreement, version […, YYYY-MM-DD]
[OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE Grant Agreement]
hereby consents to become a Party to the Consortium Agreement identified above and accepts
all the rights and obligations of a Party starting [date].
[OFFICIAL NAME OF THE COORDINATOR AS IDENTIFIED IN THE Grant Agreement]
hereby certifies that the consortium has accepted in the meeting held on [date] the accession of
[the name of the new Party] to the consortium starting [date].
This Accession document has been done in 2 originals to be duly signed by the undersigned
authorised representatives.
[Date and Place]
[INSERT NAME OF THE NEW PARTY]
Signature(s)
Name(s)
Title(s)
[Date and Place]
[INSERT NAME OF THE COORDINATOR]
Signature(s)
Name(s)
Title(s)
61 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Attachment 3: List of Third Parties for simplified transfer according to Section 8.3.2.
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Imperial Innovations Limited; Registered N° 2060639; 52 Princes Gate, Exhibition Road, London
SW7 2PG, United Kingdom; http://www.imperialinnovations.co.uk/
INRA TRANSFERT (IT)
Headquarters : 28 rue du Docteur Finlay, 75015 Paris (FRANCE)
Karolinska Institutet
Marie Löf
Paulina Nowicka
62 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Attachment 4: Identified Affiliated Entities according to Section 9.7
63 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Attachment 5: Scientific Advisory Committee Agreement according to Section 6.5.4.1
Scientific Advisory Committee – Participation and Confidentiality Agreement
This agreement is by and between:
1) Imperial College of Science, Technology and Medicine, established in Exhibition
Road, South Kensington Campus, London, SW7 2AZ, United Kingdom (“Coordinator”);
and
2) [NAME OF INDIVIDUAL Dr/Mr/Prof …], whose address for professional contacts and
communications is [address] (“Advisor”).
WHEREAS:
A. The Coordinator is the lead beneficiary of the EU H2020-funded ‘Science and Technology
in childhood Obesity Policy – STOP’ under Grant Agreement No. 774548 (hereinafter the
“Project”).
B. All organisations participating in the Project (hereinafter the “Consortium Partners” and
identified in Appendix A) have agreed to invite the Advisor to participate as a member of
the Project’s Scientific Advisory Committee (hereinafter “Advisory Board”).
C. In the context of the Advisor’s participation as a member of the Advisory Board, the
Advisor may receive certain information directly or indirectly from Consortium Partners
which the Consortium Partners wish to keep confidential.
D. In line with Section 6 of the Project’s Consortium Agreement, the Coordinator is instructed
to execute an agreement (hereinafter the “Agreement”) with the Advisor in respect of
such confidential information.
E. The Advisor agrees to be bound by the terms, conditions and limitations set out in this
Agreement with respect to confidential information.
IT IS NOW AGREED AS FOLLOWS:
1. Definitions
In this Agreement, the following words shall have the following meanings:
“Confidential Information” shall mean:
a) in respect of Information provided in documentary form
or by way of a model or in other tangible form, Information
which at the time of provision is marked or otherwise
designated to show expressly or by necessary implication
that it is imparted in confidence; and
b) in respect of Information that is imparted orally, any
Information that the Disclosing Party or its representatives
informed the Advisor at the time of disclosure was
imparted in confidence; and
64 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
c) in respect of Confidential Information imparted orally,
any note or record of the disclosure; and
d) any copy of any of the foregoing.
“Disclosing Party” shall mean any of the Consortium Partners as the party
disclosing Confidential Information directly or indirectly to
the Advisor under this Agreement.
“Effective Date” shall mean the date the last Party signs this Agreement.
“Information” shall mean information provided directly or indirectly by the
Disclosing Party to the Advisor in the course of his/her
duties as a member of the Advisory Board, whether in oral
or documentary form or by way of models, biological or
chemical materials or other tangible form or by
demonstrations and whether before, on or after the date of
this Agreement.
“Period” shall mean a period of 4 years from the end of the Project.
“Permitted Purpose” shall mean the performance of the Advisor’s duties as a
member of the Advisory Board.
2. Confidentiality. The Advisor undertakes to the Disclosing Party:
2.1. to keep and treat all Confidential Information which may be disclosed by the Disclosing
Party as confidential, secret, and the sole property of the Disclosing Party;
2.2. not to disclose or cause the Disclosing Party's Confidential Information to be disclosed in
whole or in part to any third party without the prior written consent of the Disclosing Party;
2.3. not to use the Disclosing Party’s Confidential Information in whole or in part for any
purpose except for the Permitted Purpose;
2.4. not to copy the Disclosing Party's Confidential Information other than to the extent
required for the Permitted Purpose; and
2.5. to take proper and all reasonable measures to ensure the confidentiality of the Disclosing
Party’s Confidential Information.
3. Exceptions. The provisions of Clause 2 above shall not apply to any part of the Disclosing
Party’s Confidential Information which the Advisor is clearly able to demonstrate:
3.1. was known to it prior to its receipt by the Advisor; or
3.2. was in the public domain prior to its receipt by the Advisor; or
3.3. becomes part of the public domain through no fault of the Advisor; or
3.4. becomes known to the Advisor through the action of a third party not in breach of any
relevant legal obligation of confidentiality to the Disclosing Party in respect of such
65 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Confidential Information; or
3.5. it is required to disclose by order of a court.
4. Return of information and property. The Advisor acknowledges and agrees that the
property and copyright in Confidential Information disclosed to it by a Disclosing Party,
including any documents, files and other items containing any Confidential Information,
belongs to the Disclosing Party. At the Disclosing Party's written request, the Advisor will
either return immediately to the Disclosing Party or destroy immediately all Confidential
Information which the Advisor has received under this Agreement and which may still be in
the Advisor's possession, including any copies made, and make no further use or disclosure
of any of the Confidential Information. The Advisor may, however, keep one copy of the
Disclosing Party's Confidential Information only to the extent necessary for the Advisor to
comply with applicable laws and regulations or for the purpose of enabling the Advisor to
comply with the provisions of this Agreement.
5. Period. The obligations of Confidentiality on the Advisor under this Agreement shall continue
in force for the Period.
6. No implied rights. No warranty or representation, express or implied, is given as to the
accuracy, efficacy, completeness, capabilities or safety of any Information provided under this
Agreement. This Agreement shall not be construed:
6.1. to grant the Advisor any licence or rights other than as expressly set out herein in respect
of the Confidential Information, nor
6.2. to require the Disclosing Party to disclose any Confidential Information to the Advisor.
7. Amendment. This Agreement shall not be amended except in writing by the Coordinator
with the prior written consent of the Consortium Partners and Advisor.
8. Conflict of Interests. The Advisor confirms that there is no conflict of interest between his/her
role as a member of the Advisory Board and his/her other professional interests/duties.
9. Enforcement of rights. It is understood by the Advisor that any of the Consortium Partners
may enforce its rights under this Agreement as a Disclosing Party.
10. Law and jurisdiction. This Agreement shall be governed by and construed in accordance
with Belgian Law and shall be subject to the non-exclusive jurisdiction of the Belgian courts,
except with regard to the World Health Organization (hereinafter referred to as “WHO”).
Due to its status as an international organisation, where WHO is a disclosing Party the
following applies:
Any matter relating to the interpretation or application of this Agreement which is not covered
by its terms shall be resolved by reference to Belgian law. Any dispute relating to the
interpretation or application of this agreement shall, unless amicably settled, be subject to
conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The
arbitration shall be conducted in accordance with the modalities to be agreed upon by the
parties or, in the absence of agreement, with the rules of arbitration of the international
Chamber of Commerce. The parties shall accept the arbitral award as final.
66 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Nothing contained in this Agreement shall be construed as a waiver of any of the privileges
and immunities enjoyed by the WHO under national or international law, and/or as submitting
WHO to any national court jurisdiction.
11. Signature. This Agreement may be executed in two or more counterparts, each of which will
be deemed an original, but all of which together shall constitute one and the same Agreement.
The Coordinator and Advisor acknowledge that an original signature or a copy thereof
transmitted by PDF shall constitute an original signature for the purposes of this Agreement.
For and on behalf of the For and on behalf of the
Coordinator Advisor
signed signed
print name print name
title title
date date
Appendix A: List of Consortium Partners
1. IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
2. INSTITUTO SUPERIORE DI SANITA
3. TERVISE ARENGU INSTITUUT
4. INSTITUTO DI STUDI PER L’INTEGRAZIONE DEI SISTEMI
5. UNIVERSITATEA DE MEDICINA SI FARMACIE VICTOR BABES TIMISOARA
6. INSTITUTO DE SAUDE PUBLICA DA UNIVERSIDADE DO PORTO
7. INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
8. UNIVERSITEIT HASSELT
9. EUROPEAN PUBLIC HEALTH ALLIANCE
10. WORLD OBESITY FEDERATION
11. UNIVERZA V LJUBLJANI
12. KAROLINSKA INSTITUTET
13. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE
14. SVEUČILIŠTE U ZAGREBU, KINEZIOLOŠKI FAKULTET
15. THE UNIVERSITY OF AUCKLAND
16. BARCELONA INSTITUTE FOR GLOBAL HEALTH FOUNDATION
17. UNIVERSITA DEGLI STUDI DI TORINO
18. TERVEYDEN JA HYVINVOINNIN LAITOS
19. WORLD HEALTH ORGANIZATION
20. CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.
21. DIREÇÃO-GERAL DA SAÚDE
22. UNIVERSITY OF SOUTHERN CALIFORNIA on behalf of its KECK SCHOOL OF
MEDICINE of USC
23. ETABLISSEMENT D’ENSEIGNEMENT SUPERIEUR CONSULAIRE HAUTES
ETUDES COMMERCIALES DE PARIS
24. INSTITUT DES SCIENCES AT INDUSTRIES DU VIVANT ET DE L’ENVIRONNEMENT
67 / 68
STOP Consortium Agreement, Final Version, 2018-04-04
Attachment 6: Special Clauses pertaining to the involvement of the WHO
The provisions contained in this Attachment prevail over any other provisions in this Consortium
Agreement with regard to the World Health Organization (WHO) and will survive the expiration
or early termination of this Agreement.
1. Audits
With regard to WHO, the Agreement on the application of the verification clause to operations
administered by the United Nations and financed or co-financed by the European Union
annexed to the Financial and Administrative Framework Agreement concluded by the Union,
represented by the Commission, and the United Nations on 29.04.2003 (also referred to as the
"FAFA" - to which WHO adhered on the 11.12.2003), as amended with effect from 1 January
2014, prevail over this Agreement with regard to any provisions dealing with the same issues.
2. Reference Law
Concerning WHO, any matter relating to the interpretation or application of this Consortium
Agreement not covered by its terms shall be resolved by reference to the law of Belgium,
supplemented, where appropriate, by the general principles governing the law of international
organisations and the rules of general international law.
3. Privileges and Immunities
Nothing in this Consortium Agreement shall be interpreted as a waiver of the privileges or
immunities accorded to WHO by its constituent documents or international law. As such, WHO
is not subject to any national legislation, jurisdiction or enforcement measures
4. Liability
In view of its status as a public international organization which enjoys privileges and
immunities, WHO will indemnify for loss, damage or injury to third parties only in cases where
its responsibility has been established and agreed.
5. Administration of funds
Funds received by WHO shall be administered in accordance with the Financial Regulations
and Rules, and financial and administrative rules and practices of WHO.
6. Ethics Review Committee
WHO's involvement in the Project is subject to review and approval by its Ethics Review
Committee, as necessary and appropriate.
7. Commercial products
Any commercial product which may result from the WHO’s research and development work
undertaken as a result of the Project shall be made widely available on reasonable terms,
including in particular to the public sector of developing countries at an affordable price.
68 / 68
*/
Virve-Hella Haavam
Rahandusministeerium
[email protected] Meie 02.09.2019 nr 1.8-1/2161-1
Tervise Arengu Instituudi taotlus
sildfinantseerimise avamiseks (9T90-STOP)
Lugupeetud Virve-Hella Haavam
Palun avada Tervise Arengu Instituudile programmi „Horizon 2020“ välistoetuse „Science
and Technology in childhood Obesity Policy“ (9T90-STOP) sildfinantseering 2019 aastaks
summas 20 000 eurot.
Projekt: Programm „Horizon 2020“ toetus „Science and Technology in
childhood Obesity Policy“
Akronüüm: STOP
Tunnus SAP-is: 9T90-STOP
Nimetus SAP-is: STOP - Science and Technology in childhood Obesity Policy
Projekti periood: 01.06.2018-31.05.2022 ja eelarve 132 463,26 eurot
Lugupidamisega
(allkirjastatud digitaalselt)
Ester Timmas
toetuste juht
Lisa: 1. Sildfinantseeringu taotlemine 2019 aastaks 1T90-STOP.xlsx
2. Leping_18-2-15_169.pdf
Ülle Näksi 6269710
[email protected]
Suur-Ameerika 1 / 10122 Tallinn / 626 9301 /
[email protected] / www.sm.ee / registrikood 70001952